Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study

Michael B. Ranke, M. O. Savage, P. G. Chatelain, M. A. Preece, Ronald (Ron) Rosenfeld, P. Wilton

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

A total of 33 patients (17 female, 16 male) with Laron syndrome (n = 31) or hGH-1 gene (n = 2, type IA deletion) from 22 centres in 12 countries were enrolled in a study conducted by Pharmacia and Upjohn, Stockholm, which was designed to test the efficacy, in terms of growth promotion and safety, of IGF-I (Igef(TM)). The patients were treated with 40-120 μg/kg IGF-I s.c. twice daily after meals. After the study ended, the patients continued to be treated on an individual basis. The results of 17 patients, who were treated for 48 months or longer were available for the present analysis. Six patients were treated for up to 72 months. When treatment started, the mean age of these patients (8 female, 9 male) was 9.1 (3.7-13.5) years and mean height was -6.5 ± 1.3 SDS. At the end of the observation period, the mean age of the 17 patients was 14.2 (9.7-17.7) years and mean height was -4.9 ± 1.9 SDS. All patients showed a significant increase in growth during the final year on IGF-I, with two of them reaching the age-corresponding 3rd centile. The total gain in height (ΔHT) was 1.7 ± 1.2 SDS. ΔHT SDS correlated negatively with age at onset of treatment (R2 = -0.78, p <0.02). BMI was 0.6 ± 1.8 SDS at start of treatment and 1.8 ± 1.5 SDS at the end of observation. Total ΔHT SDS correlated positively with total ΔBMI SDS (R2 = 0.59, p <0.01). Long-term treatment of patients with GHIS thus proved to be effective in promoting growth. If treatment is started at an early age, there is considerable potential for achieving height normalisation. The treatment modalities need to be optimized with respect to the growth-promoting and metabolic effects of IFG-I.

Original languageEnglish (US)
Pages (from-to)128-134
Number of pages7
JournalHormone Research
Volume51
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Laron Syndrome
Insulin-Like Growth Factor I
Multicenter Studies
Therapeutics
Growth
Observation
Age of Onset
Meals

Keywords

  • Growth hormone insensitivity
  • IGF-I
  • Laron syndrome
  • Treatment

ASJC Scopus subject areas

  • Endocrinology

Cite this

Ranke, M. B., Savage, M. O., Chatelain, P. G., Preece, M. A., Rosenfeld, R. R., & Wilton, P. (1999). Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Hormone Research, 51(3), 128-134. https://doi.org/10.1159/000023345

Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. / Ranke, Michael B.; Savage, M. O.; Chatelain, P. G.; Preece, M. A.; Rosenfeld, Ronald (Ron); Wilton, P.

In: Hormone Research, Vol. 51, No. 3, 1999, p. 128-134.

Research output: Contribution to journalArticle

Ranke, MB, Savage, MO, Chatelain, PG, Preece, MA, Rosenfeld, RR & Wilton, P 1999, 'Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study', Hormone Research, vol. 51, no. 3, pp. 128-134. https://doi.org/10.1159/000023345
Ranke, Michael B. ; Savage, M. O. ; Chatelain, P. G. ; Preece, M. A. ; Rosenfeld, Ronald (Ron) ; Wilton, P. / Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. In: Hormone Research. 1999 ; Vol. 51, No. 3. pp. 128-134.
@article{a1747bb5e6934db3880f9ff4da69b590,
title = "Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study",
abstract = "A total of 33 patients (17 female, 16 male) with Laron syndrome (n = 31) or hGH-1 gene (n = 2, type IA deletion) from 22 centres in 12 countries were enrolled in a study conducted by Pharmacia and Upjohn, Stockholm, which was designed to test the efficacy, in terms of growth promotion and safety, of IGF-I (Igef(TM)). The patients were treated with 40-120 μg/kg IGF-I s.c. twice daily after meals. After the study ended, the patients continued to be treated on an individual basis. The results of 17 patients, who were treated for 48 months or longer were available for the present analysis. Six patients were treated for up to 72 months. When treatment started, the mean age of these patients (8 female, 9 male) was 9.1 (3.7-13.5) years and mean height was -6.5 ± 1.3 SDS. At the end of the observation period, the mean age of the 17 patients was 14.2 (9.7-17.7) years and mean height was -4.9 ± 1.9 SDS. All patients showed a significant increase in growth during the final year on IGF-I, with two of them reaching the age-corresponding 3rd centile. The total gain in height (ΔHT) was 1.7 ± 1.2 SDS. ΔHT SDS correlated negatively with age at onset of treatment (R2 = -0.78, p <0.02). BMI was 0.6 ± 1.8 SDS at start of treatment and 1.8 ± 1.5 SDS at the end of observation. Total ΔHT SDS correlated positively with total ΔBMI SDS (R2 = 0.59, p <0.01). Long-term treatment of patients with GHIS thus proved to be effective in promoting growth. If treatment is started at an early age, there is considerable potential for achieving height normalisation. The treatment modalities need to be optimized with respect to the growth-promoting and metabolic effects of IFG-I.",
keywords = "Growth hormone insensitivity, IGF-I, Laron syndrome, Treatment",
author = "Ranke, {Michael B.} and Savage, {M. O.} and Chatelain, {P. G.} and Preece, {M. A.} and Rosenfeld, {Ronald (Ron)} and P. Wilton",
year = "1999",
doi = "10.1159/000023345",
language = "English (US)",
volume = "51",
pages = "128--134",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study

AU - Ranke, Michael B.

AU - Savage, M. O.

AU - Chatelain, P. G.

AU - Preece, M. A.

AU - Rosenfeld, Ronald (Ron)

AU - Wilton, P.

PY - 1999

Y1 - 1999

N2 - A total of 33 patients (17 female, 16 male) with Laron syndrome (n = 31) or hGH-1 gene (n = 2, type IA deletion) from 22 centres in 12 countries were enrolled in a study conducted by Pharmacia and Upjohn, Stockholm, which was designed to test the efficacy, in terms of growth promotion and safety, of IGF-I (Igef(TM)). The patients were treated with 40-120 μg/kg IGF-I s.c. twice daily after meals. After the study ended, the patients continued to be treated on an individual basis. The results of 17 patients, who were treated for 48 months or longer were available for the present analysis. Six patients were treated for up to 72 months. When treatment started, the mean age of these patients (8 female, 9 male) was 9.1 (3.7-13.5) years and mean height was -6.5 ± 1.3 SDS. At the end of the observation period, the mean age of the 17 patients was 14.2 (9.7-17.7) years and mean height was -4.9 ± 1.9 SDS. All patients showed a significant increase in growth during the final year on IGF-I, with two of them reaching the age-corresponding 3rd centile. The total gain in height (ΔHT) was 1.7 ± 1.2 SDS. ΔHT SDS correlated negatively with age at onset of treatment (R2 = -0.78, p <0.02). BMI was 0.6 ± 1.8 SDS at start of treatment and 1.8 ± 1.5 SDS at the end of observation. Total ΔHT SDS correlated positively with total ΔBMI SDS (R2 = 0.59, p <0.01). Long-term treatment of patients with GHIS thus proved to be effective in promoting growth. If treatment is started at an early age, there is considerable potential for achieving height normalisation. The treatment modalities need to be optimized with respect to the growth-promoting and metabolic effects of IFG-I.

AB - A total of 33 patients (17 female, 16 male) with Laron syndrome (n = 31) or hGH-1 gene (n = 2, type IA deletion) from 22 centres in 12 countries were enrolled in a study conducted by Pharmacia and Upjohn, Stockholm, which was designed to test the efficacy, in terms of growth promotion and safety, of IGF-I (Igef(TM)). The patients were treated with 40-120 μg/kg IGF-I s.c. twice daily after meals. After the study ended, the patients continued to be treated on an individual basis. The results of 17 patients, who were treated for 48 months or longer were available for the present analysis. Six patients were treated for up to 72 months. When treatment started, the mean age of these patients (8 female, 9 male) was 9.1 (3.7-13.5) years and mean height was -6.5 ± 1.3 SDS. At the end of the observation period, the mean age of the 17 patients was 14.2 (9.7-17.7) years and mean height was -4.9 ± 1.9 SDS. All patients showed a significant increase in growth during the final year on IGF-I, with two of them reaching the age-corresponding 3rd centile. The total gain in height (ΔHT) was 1.7 ± 1.2 SDS. ΔHT SDS correlated negatively with age at onset of treatment (R2 = -0.78, p <0.02). BMI was 0.6 ± 1.8 SDS at start of treatment and 1.8 ± 1.5 SDS at the end of observation. Total ΔHT SDS correlated positively with total ΔBMI SDS (R2 = 0.59, p <0.01). Long-term treatment of patients with GHIS thus proved to be effective in promoting growth. If treatment is started at an early age, there is considerable potential for achieving height normalisation. The treatment modalities need to be optimized with respect to the growth-promoting and metabolic effects of IFG-I.

KW - Growth hormone insensitivity

KW - IGF-I

KW - Laron syndrome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032771876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032771876&partnerID=8YFLogxK

U2 - 10.1159/000023345

DO - 10.1159/000023345

M3 - Article

VL - 51

SP - 128

EP - 134

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 3

ER -